xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

205

ICAR SINONASAL TUMORS

TABLE XXII.A.1 (Continued) Study

Year LOE Study design Study groups

Clinical endpoints Conclusion

1. CD8 + TILs and TMIT were correlated with the histological subtype of ITAC and with improved OS 2. The modest percentage of CD8 high/PD-L1-positive cases indicates that ITAC is a lowly immunogenic tumor type 3. Sinonasal ITACs, especially the papillary and colonic subtypes, may benefit from 1. Surgery and RT associated with improved OS 2. Advanced age, comorbidities, advanced tumor grade, and stage associated with worse OS 3. Chemotherapy not associated withOS extension to the contralateral nasal fossa at preoperative imaging and intraoperative assessment can be safely managed with unilateral resection 2. Unilateral resection provides shorter hospitalization, preservation of some olfactory function, and oncological outcomes comparable to bilateral resection 3. Occupational exposure to wood dusts or other inhalants is not per se an indication for bilateral resection Factors influencing survival rates are local recurrence, development of distant metastases, tumor stage (pT classification), and infiltrated surgical margins Prognostic factors for both OS and DFS included pT stage, margin status, and tumor grade therapy with immune checkpoint inhibitors 1. ITAC confined to one ethmoid without any

To evaluate CD8 + TILs and TMIT

Garcìa-Marìn et al. 1163

2020 4

Retrospective case series

133 cases of sinonasal ITAC treated with primary surgery followed by

(combining CD8 + TILs and PD-L1) as predictive biomarkers for immunotherapy

adjuvant RT (in selected cases)

Patel et al. 1164

2020 4

Retrospective database study (NCDB)

553 cases of

OS

adenocarcinoma No distinction between ITAC and non-ITAC

1. OS 2. DSS 3. RFS 4. LRFS 5. Morbidity and functional

Schreiber et al. 374

54 cases of sinonasal ITAC divided into

2018 4

Retrospective

case–control study

two groups: patients treated with unilateral ERTC ( n = 27) versus patients treated with bilateral ERTC ( n = 27)

outcomes between the two groups

Campet al. 1161

2016 4

Retrospective

123 cases of sinonasal ITAC surgically treated with EEA

1. OS 2. DSS 3. RFS

case–control study

Nicolai et al. 1146 2016 4

1. OS 2. DFS

169 cases of sinonasal ITAC surgically treated with EEA with or without transnasal craniectomy or combined CFR followed by postoperative RT (in selected cases)

Retrospective

case–control study

(Continues)